Resultados de la búsqueda 581-590 of 15233 for immunothérapie Bylaska
... immunotherapy for patients who have stage IV metastatic melanoma. Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory ...
The four cancer types are: Non-Small Cell Lung Cancer (NSCLC) and melanoma that are progressing on checkpoint inhibitor (CPI, generally refers to anti-PD(L)1 ...
The purpose of this study is to evaluate the effects of ibrutinib and rituximab with or without venetoclax in treating patients with previously untreated ...
The primary purpose of the pilot study is to evaluate the safety and tolerability of an autologous dendritic cells (DC) vaccine delivered by intra-tumoral ...
Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options. One of the barriers to improving ...
The purpose of this study is to evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or ...
Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor ...
El Departamento de anestesiología de Mayo Clinic atiende a más de 145.000 pacientes cada año y combina la atención, la investigación y la educación del ...
The purpose of this study is to determine if a new drug combination, pirtobrutinib and venetoclax, will help Chronic Lymphocytic Leukemia (CLL) or Small ...
... immunotherapy, or chemoimmunotherapy. Brain Tumor Repository. Scottsdale/Phoenix, Ariz. The main objective of the Brain Tumor Repository is to allow access ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?